Covid-19 testing in Srinagar, Kashmir | Representational photo | ANI
Covid-19 testing in Srinagar, Kashmir | Representational photo | ANI
Text Size:

New Delhi: The Oxford University-led Covid vaccine project, partnered by Swedish-British firm AstraZeneca and Pune-based Serum Institute of India (SII), Friday came one step closer to human trials in the country, ThePrint has learnt.

The subject expert committee, which advises regulator Drug Controller General of India (DCGI) on proposals seeking approvals for new drugs, vaccines or clinical trials, Friday approved the revised protocol submitted by SII to kick-start human trials in India. 

The protocol will now be moved to DCGI V.G. Somani, who is likely to take a “decision by the end of the week” given the urgency of the Covid challenge.

“The SEC has accepted the revised protocol submitted by the company. It has recommended the company’s application for starting human trials across India to the DCGI,” said a senior government officer privy to the developments. “The final decision is likely to be taken before the end of this week.” 

The Oxford vaccine candidate is among the frontrunners in the race to develop an effective preventive against Covid-19. SII has a tie-up with Swedish-British pharma giant AstraZeneca for the Oxford vaccine. The company is expected to manufacture a billion doses for low- and middle-income countries by 2021.

The SEC’s nod follows a whirlwind three days where the panel asked SII to rework eight points on a protocol submitted this Tuesday. The SEC meeting Friday was called urgently as SII, it is learnt, sent a revised proposal “within hours” of the Central Drugs Standard Control Organisation (CDSCO) expert committee submitting its recommendation. 

The panel had sought changes in eight parameters, including distribution of sites and dropout rate.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.


Also Read: Two Asian pharma companies hold key to Oxford vaccine, China woos ASEAN & other Covid news

Changes sought

The SEC is an advisory panel that studies the proposals for new drugs, vaccines or clinical trials and advises the DCGI, who heads the CDSCO, on final approvals. 

According to the revised proposal, over 1,600 people will participate in the trials in 20 select cities across India. 

The changes sought in the SII’s suggested protocol included incorporating a pan India distribution of trial sites. According to the minutes of the SEC’s meeting Tuesday, a copy of which has been accessed by ThePrint, the panel also instructed SII to “demarcate the phase II and phase III part of the protocol”. 

The CDSCO panel also asked SII to “specify the role of the ICMR”.   

“Immunogenicity shall be either primary or secondary objective,” the minutes said. Immunogenicity means the ability of a foreign substance to provoke the body and create an immune response.

It also asked for “interim analysis of immunogenicity cohort to be carried out only after day 58 both for safety and immunogenicity.”

Also Read: Why in this race to Covid-19 vaccine the world will need more than one winner



Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

Share Your Views


Please enter your comment!
Please enter your name here